Select Bibliography

Filter by any of these (after searching):

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 12 items

Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma

Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017

Abstract - Primary - Primary - Neuro-Onc - A071101

Long term outcomes from intergroup NCCTG 86-72-51 (Alliance): Final report of a phase III prospective randomized trial of high dose versus low dose radiation therapy in adults with supratentorial low-grade glioma.

Breen, William G. , Anderson, S. Keith , Carrero, Xiomara W ... - SNO - Neuro-Oncology - 2019

Abstract - Primary - Long-Term-Followup - Neuro-Onc - NCCTG-85-72-51

NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases.

Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - SNO - Neuro Oncol - 2015

Abstract - Primary - Primary - Neuro-Onc - N0574

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma multiforme: a north central cancer treatment group study.

Friday, B. B. , Buckner, J. , Anderson, S. K. , Giannini, C. ... - SNO - 15th Annual Meeting of the Society for Neuro-Oncology (SNO) - 2010

Abstract - Primary - Primary - Neuro-Onc - N0779

NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (RGBM).

Galanis, E. , Anderson, S. K. , Lafky, J. M. , Kaufmann, T. J. ... - SNO - Neuro-oncology - 2011

Abstract - Primary - Primary - Neuro-Onc - N0776

NCCTG N0272: phase II trial of imatinib mesylate; (gleevec; sti571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma: a north central cancer treatment group study.

Jaeckle, K. A. , Anderson, S. K. , Kosel, M. , Sarkaria, J. ... - SNO - Neuro-oncology - 2011

Abstract - Primary - Primary - Neuro-Onc - N0272

CODEL: Phase III study of RT alone, RT plus temozolomide, or temozolomide alone for newly diagnosed 1P/19Q codeleted anaplastic oligodendroglioma patients. Updated analysis from the initial study design (NCCTG N0577, Alliance)

Jaeckle, Kurt A. , Ballman, Karla V. , van den Bent, Martin ... - SNO - Neuro-Oncology - 2020

Abstract - Primary - Other - Neuro-Onc - N0577

CODEL (Alliance N0577; EORTC 26081/22086 ; NRG 1071; NCIC CEC-2): A Phase III Randomized Intergroup Study for patients (pts) with newly diagnosed 1p/19q codeleted anaplastic glioma. Preliminary analysis of patients treated on the original protocol design with RT vs. RT + concomitant/adjuvant TMZ vs. TMZ alone

Jaeckle, Kurt , Voglebaum, Michael , Ballman, Karla ... - SNO - Neuro Oncol - 2015

Abstract - Primary - Comprehensive - Neuro-Onc - N0577

Improved outcome in recurrent glioblastoma (RGBM) patients treated with bevacizumab (BEV) and sorafenib (SOR) is predicted by a greater drop in apparent diffusion coefficient (ADC) on MRI imaging.

Kaufmann, T. J. , Anderson, S. K. , Jaeckle, K. A. , Uhm, J. H. ... - SNO - 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors - 2011

Abstract - Secondary-not-in-original - Primary - Neuro-Onc - N0776

N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group): Phase III Trial of Post-Operative Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease: Cognitive function of long-term survivors

Roberge, David , Ballman, Karla V. , Cerhan, Jane H. ... - SNO - Neuro-Oncology - 2017

Abstract - Secondary - Primary - Neuro-Onc - N107C

Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572

Schiff, D. , Sarkaria, J. , Decker, P. , Buckner, J. , Galanis, E. ... - SNO - Neuro-oncology - 2009

Abstract - Primary - Preliminary - Neuro-Onc - N0572

Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572

Schiff, D. , Sarkaria, J. , Decker, P. , Buckner, J. , Galanis, E. ... - SNO - Neuro-oncology - 2007

Abstract - Primary - Preliminary - Neuro-Onc - N0572